Close Menu

Breaking News

The drug is approved as a maintenance treatment for platinum-responsive metastatic pancreatic cancer patients with germline BRCA1/2 mutations.

The firm had received interest from unnamed potential acquisition partners following the departure of its CEO, but it has decided to remain as a standalone business.

Roche will pay Codexis royalties under a worldwide license to include EvoT4 DNA ligase in next-generation sequencing products and workflows.

The budget for fiscal year 2020 includes increases for each of the NIH's institutes and centers, as well as the FDA and the NSF.

The score's developers also suggest that current guidelines for stroke prevention may not be sufficient for individuals at higher genomic risk for the condition.

The LRT BAL panel detects a wide spectrum of clinically relevant causative agents, such as atypical pathogens and antibiotic resistance markers.

New research suggests that a set of common variants on chromosome 22 may influence heart defects associated with a condition called 22q11.2 deletion syndrome.

News items for the week of Dec. 16, 2019.

Simulations suggested prostate cancer screening informed by polygenic risk scores is more cost effective and less prone to overdiagnoses than screening based on age alone.

Two recent CRISPR-Cas9 viability screens in cancer cell lines were concordant across multiple metrics despite significant differences in experimental protocols.

TC agreed with a judge who said that 10x's older GEM microfluidic chips infringed Bio-Rad patents, but that the firm's new Next GEM chips did not.

The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.

The exclusive distribution deal expands the Finnish bioinformatics software company's footprint in the Middle East, Africa, and Asia.

Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.

The company has raised $30 million to date to fund development and commercialization of its molecular diagnostic test to predict response to anti-TNF therapies.

St. Jude Children's Research Hospital researchers evaluated a microbial cell-free DNA sequencing test from infectious disease diagnostics firm Karius.

Effective Feb. 3, 2020, the donor-derived cell-free DNA test will be covered for all kidney transplant recipients, including those with multiple kidney transplants.

Investigators analyzed the expression of protein-coding genes in 18 blood immune cell populations, comparing the expression profiles with those in other cell and tissue types.

The firm did an initial close of its Series A financing round and will pursue additional investments during Q1 2020 when the round is anticipated to close.

Promega said it plans to use the technology to create new research products for investigating endogenous biology.

The financing was led by HealthQuest Capital, with participation from 5AM Ventures and RareCyte founder Ron Seubert, and follows a $30 million round in 2017.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.